Abstracts
Bischof M, Briel M, Bucher HC, Nordmann A University Hospital Basel, Basel, BS, Switzerland OBJECTIVES: Drug eluting stents (DES) are more effective than bare metal stents (BMS) in preventing angiographic and clinical restenosis. Within this study the cost-effectiveness of sirolimus (SES) and paclitaxel eluting stents (PES) compared to BMS was estimated for a UK setting with data from a meta-analysis. METHODS: A probabilistic Markov model was constructed. The model includes events observed in clinical trials (MI, revascularisation, CABG) and the health states heart failure and stroke. The meta-analysis data comprised 3-year follow-up data from randomized controlled trials. Probability distributions were fitted to all transition probability, cost and quality of life (QoL) parameters. Univariate sensitivity analysis was performed on several parameters. Effects and costs were discounted at 3%, the time horizon was 3 years and the number of stents was 1.27 per patient. A health care perspective was adopted. QoL data was obtained from published studies. RESULTS: The incremental costs for SES patients are €712 (95% CI: −2431-1715) and €1101 (95% CI: 150-1493) for PES patients. DES yield less QALYs than BMS with −0.0156 incremental QALYs (95% CI: −0.2652-0.2302) per SES patient and −0.0077 incremental QALYS (95% CI: −0.0777-0.06643) per PES patient compared to BMS patients. At a threshold level of Euros 50'000 per QALY the incremental net monetary benefit per SES patient is €−1492 (95% CI: −14213-10766) and €−1484 (95% CI: −5004-2273) per PES patient. At the same threshold level SES have a 35% probability of being cost-effective, PES have a probability of 17% of being cost-effective. CONCLUSIONS: Three-year follow up data show that DES are less effective than BMS when mortality is taken into account. Given the higher costs per DES patient, DES are dominated by BMS. Althoug DES show favourable results over BMS concerning revascularisation rates, they are not cost-effective. ) and costs (semifixed and direct). A logistic regression analysis was made to fit the model. The costs were contrasted by covariance analysis (ANCOVA-marginal means). Data were analyzed using SPSS-v12 and p values of <0.05 were taken as the level of statistical significance. RESULTS: Ninehundred patients were seen for COPD; mean age 70.4 ± 9.8 years and 85.3% were males. Around 19.0% (n = 171) had undergone a CVE (CI: 16.4-21.6%); 15.1% with IHD. The main CVRFs were: 44.1%-hypertension, 36.2%-obesity, 31.9%-dyslipidemia, 23.6%-diabetes and 22.7%-smoking. The mean morbidity/ patient/year was 10.1 ± 4.2 with CVEs vs. 8.3 ± 4.3 (p = 0.000); the clinical parameters studied (FEV 1 , BMI) showed no significance. The logistic model, corrected for age-sex and severity identified as associated factors: diabetes mellitus (OR = 2.1; CI = 1.3-3.4; p = 0.001) and dyslipidemia (OR = 1.7; CI = 1.1-2.7; p = 0.002). Quantification of unit cost/year/COPD was €2793.22 ± 3166.30 (70.5% pharmaceutical expenditure). The cost/year/patient-adjusted was €2847.22 (SE = 117.02) without CVEs, versus €2563.66 (SE = 244.05) with CVEs, p = NS. CON-CLUSIONS: The presence of CVEs associated with COPD is high, causing an important co-morbidity, though without increasing the global costs of the disease. Diabetes mellitus and dyslipidemia are the main CVRFs associated; their prevention could improve the disease outcomes. Further studies are needed to confirm the consistency of these results. To identify key factors determining therapeutic decision making concerning coronary artery disease treatment in the GPs' and specialists' practices. To establish role of economic factors related. METHODS: A survey was conducted on the representative sample of Polish physicians (184 GPs and 63 specialists in the outpatient clinics) dealing with coronary artery disease (CAD) patients. Data were obtained with the aid of a specific questionnaire, including 6 items completed by doctor. RESULTS: Choosing the treatment for a CAD patient, 75% of the GPs and specialists have taken drugs' efficacy into consideration at first. Safety of treatment (GPs 9.8% and specialists 12.7% respectively) and adherence to guidelines (9.2%; 9.5%) were rarely considered as main factors. One third of the GPs and specialists declared that unbearable drugs' costs constituted the most frequent reason for treatment discontinuation. The adverse events (20.6% and 20.1%) and poli-therapy (20.6% and 19.6%) were the next reasons cited. Treatment with the lowest priced drugs (75%; 74%) and those medicines administered once a day (75%; 71%) were described as two best ways of compliance improvement. The most important factors leading to the change of treatment were insufficient efficacy (88%) and adverse events (81%). 70% of GPs and 74% of specialists declared, that every third patient talked about economic issues of treatment (copayment, costs of diagnostic procedures and additional doctors' consultations). Only 31.5% of the GPs and 41.3% of specialists indicated an influence on the quality of life among the top three most important factors determining a therapeutic decision. CONCLUSIONS: Factors determining therapeutic decisions in the CAD patients are quite similar among the GPs and specialists. Efficacy and safety of therapy represented factors commonly reported by the GPs as well as specialists. Unbearable cost of pharmacotherapy was considered as one of the main causes leading to treatment discontinuation and incompliance. 
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PCV57 COSTS ASSOCIATED WITH DRUG USE IN THE NON-ADHERENCE TO CHOLESTEROL MANAGEMENT GUIDELINES FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN AN ELDERLY POPULATION:THE ROTTERDAM STUDY
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PCV60 A CARE MAP FOR CHF IN THE UK
Knight CJ Heron Evidence Development Ltd, Letchworth, UK OBJECTIVES: To develop a care map for Congestive Heart Failure (CHF) in the UK, covering diagnosis, progression and treatment of patients, focussing on points of interaction with the UK NHS. METHODS: Available literature was searched for national and local clinical guidelines and treatment algorithms for CHF in the UK. Ten experts were consulted to validate and complete the dataset. An interactive 1-year care map of CHF care in the UK was then developed in MS Excel. New York Heart Association (NYHA) bands I to IV were used to group patients by disease severity and costs were estimated from an NHS perspective for 2005. Patient transition between hospital (including readmissions), home and nursing home was modelled. Possible surgical interventions were: heart transplantation, valve repair and ICD. Summary statistics included: Patient disposition and location after 1 year, total estimated costs (including where accrued) and hospitalisation rates due to CHF. RESULTS: Over one year, 878,000 existing CHF patients plus 63,000 new cases would cost the NHS £896 million. The total spend (and percentage) on patients in hospital, at home and in nursing homes were £550 million (62%), £298 million (33%) and £47 million (5%) respectively. Surgery accounted for £13 million of hospital costs. Of 941,000 CHF patients, 291,000 will be hospitalised
